201 related articles for article (PubMed ID: 26312576)
1. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.
Krantz E; Trimpou P; Landin-Wilhelmsen K
J Clin Endocrinol Metab; 2015 Sep; 100(9):3251-9. PubMed ID: 26312576
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial.
Landin-Wilhelmsen K; Nilsson A; Bosaeus I; Bengtsson BA
J Bone Miner Res; 2003 Mar; 18(3):393-405. PubMed ID: 12619921
[TBL] [Abstract][Full Text] [Related]
3. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
4. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
5. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial.
Di Daniele N; Carbonelli MG; Candeloro N; Iacopino L; De Lorenzo A; Andreoli A
Pharmacol Res; 2004 Dec; 50(6):637-41. PubMed ID: 15501704
[TBL] [Abstract][Full Text] [Related]
6. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.
Dawson-Hughes B; Harris SS; Krall EA; Dallal GE
N Engl J Med; 1997 Sep; 337(10):670-6. PubMed ID: 9278463
[TBL] [Abstract][Full Text] [Related]
7. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
8. Letter to the Editor: Comment on "Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study" by Kratz E., et al.
Salvatori R
J Clin Endocrinol Metab; 2015 Nov; 100(11):L107. PubMed ID: 26544657
[No Abstract] [Full Text] [Related]
9. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
Wilhelm B; Kann PH
Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
13. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
16. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
17. Bone: Antifracture efficacy of growth hormone-confirmation at long last.
Holmes D
Nat Rev Endocrinol; 2015 Nov; 11(11):631. PubMed ID: 26391976
[No Abstract] [Full Text] [Related]
18. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
[TBL] [Abstract][Full Text] [Related]
19. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
[TBL] [Abstract][Full Text] [Related]
20. Response to the Letter by Salvatori R.
Krantz E; Trimpou P; Landin-Wilhelmsen K
J Clin Endocrinol Metab; 2015 Nov; 100(11):L108. PubMed ID: 26544658
[No Abstract] [Full Text] [Related]
[Next] [New Search]